10-K: Venus Concept Inc. Outlines Financials and Governance in Annual 10-K Filing

Venus Concept Inc.'s annual 10-K filing details its financial status, stock information, and corporate governance practices.

Summary

• Venus Concept Inc. has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, which is its common stock.
• As of December 31, 2023, there were 5,529,149 shares of common stock outstanding, along with various series of preferred stock and shares issuable upon exercise of options and warrants.
• The company's authorized capital stock consists of 300,000,000 shares of common stock and 10,000,000 shares of preferred stock.
• Holders of common stock are entitled to one vote per share and are eligible to receive dividends if declared by the board, though current debt instruments restrict dividend payments.
• In the event of liquidation, common stockholders will share ratably in net assets after debts and preferred stock liquidation preferences are satisfied.
• The company's charter and bylaws include provisions that could make it more difficult to acquire the company or remove incumbent officers and directors.
• Venus Concept is subject to Delaware's anti-takeover statute, which prohibits business combinations with interested stockholders for three years unless approved in a prescribed manner.
• The company's board is divided into three classes with staggered three-year terms, and directors can only be removed for cause with a 66 2/3% stockholder vote.
• Special stockholder meetings can only be called by the board, CEO, or president, not by stockholders.
• Stockholders cannot act by written consent without a meeting.
• The Court of Chancery of the State of Delaware is the exclusive forum for certain legal actions against the company, while federal district courts are the exclusive forum for Securities Act claims.
• The company's revenues for the year ended December 31, 2023, were $76.4 million, with a net loss of $37.2 million and an Adjusted EBITDA loss of $20.3 million.
• The company's revenues for the year ended December 31, 2022, were $99.5 million, with a net loss of $43.7 million and an Adjusted EBITDA loss of $25.4 million.
• Approximately 33% of the company's system revenues were derived from its subscription model in 2023, compared to 42% in 2022.
• The company launched Venus Prime, a structured in-house financing program, in January 2024, replacing the legacy subscription program for new customers in North America.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are positive aspects such as the launch of Venus Prime and a focus on innovation, the company's financial performance is concerning, with declining revenues, net losses, and an Adjusted EBITDA loss. The company also faces significant risks and challenges, including the need for additional financing and potential delisting from the Nasdaq Capital Market. The overall sentiment is cautious and suggests a need for significant improvements in financial performance and risk management.

Positives

• The company has a diverse range of technologies and products in the aesthetic and hair restoration markets.
• The company is expanding into non-traditional markets, such as family medicine and medical spas.
• The company has a global presence, operating in over 60 countries.
• The company has a new financing program, Venus Prime, which offers payment flexibility to customers.
• The company has a strong focus on research and development, with a pipeline of new products and technologies.

Negatives

• The company has recurring net operating losses and negative cash flows from operations.
• The company's ability to pay dividends is restricted by current debt instruments.
• The company's charter and bylaws include provisions that could make it more difficult to acquire the company.
• The company is subject to Delaware's anti-takeover statute.
• The company's board is divided into three classes with staggered three-year terms, which may make it difficult for stockholders to replace a majority of the directors.
• The company's revenue decreased from $99.5 million in 2022 to $76.4 million in 2023.
• The company's net loss was $37.2 million in 2023, compared to $43.7 million in 2022.
• The company's Adjusted EBITDA loss was $20.3 million in 2023, compared to $25.4 million in 2022.

Risks

• The company's evaluation of strategic alternatives may not result in any transaction.
• The company is exposed to the credit risk of certain customers and distributors.
• Unfavorable macroeconomic conditions may adversely impact the company's business.
• The company's recurring losses from operations and negative cash flows raise substantial doubt about its ability to continue as a going concern.
• Global supply chain disruption and inflation may have a material adverse effect on the company's business.
• The company's loan and security agreements contain restrictions that may limit its flexibility to effectively operate its business.
• The company will require additional financing to achieve its goals, and a failure to obtain this necessary capital could force it to delay, limit, reduce or terminate its operations.
• The company's financial results may fluctuate unpredictably.
• The clinical trial process required to obtain regulatory clearances or approvals is lengthy and expensive with uncertain outcomes.
• The company may not be able to adequately protect its intellectual property rights throughout the world.
• The company's devices and operations are subject to extensive government regulation and oversight.
• The company conducts a significant portion of its operations in Israel, which may be adversely affected by political, economic and military conditions.
• The company may not be able to maintain its listing on the Nasdaq Capital Market.
• The market price of the company's common stock may be volatile.
• The company does not intend to pay dividends on its common stock.
• If the company sells shares of its common stock in future financings, stockholders may experience immediate dilution.

Future Outlook

The company expects to continue to incur substantial operating losses and negative cash flows from operations until it generates revenue at a level to support its cost structure. The company plans to fund its operations and capital expenditures with cash on hand, borrowings, and issuances of capital stock until it achieves profitability. The company is also evaluating strategic alternatives to enhance stockholder value.

Management Comments

• Management plans to fund its operations and capital expenditures with cash on hand, borrowings, and issuance of capital stock until the company achieves profitability.
• Management is focused on improving cash generation and reducing exposure to defaults and increased bad debt expense.
• Management is focused on providing a complete set of products and services to the hair restoration market.
• Management believes that robotics, machine vision and artificial intelligence can provide significant improvements in the execution and performance of a broad range of non-invasive and minimally invasive aesthetic procedures.

Industry Context

The aesthetic and hair restoration markets are large and growing, with a mix of surgical and non-surgical procedures. The company competes with other medical technology and aesthetic companies, including those offering products and services unrelated to skin treatment. There has been consolidation in the aesthetic industry leading to companies combining their resources, which increases competition and could result in increased downward pressure on system prices.

Comparison to Industry Standards

• The company's revenue decline from $99.5 million in 2022 to $76.4 million in 2023 indicates a challenging year, especially when compared to the growth trends seen in some other medical technology companies.
• The company's net loss of $37.2 million in 2023, while an improvement from the $43.7 million loss in 2022, still highlights the need for improved profitability, which is a common challenge for growth-stage medical device companies.
• The company's Adjusted EBITDA loss of $20.3 million in 2023, compared to $25.4 million in 2022, shows some progress in controlling operating expenses, but further improvements are needed to reach profitability.
• The shift from 42% subscription revenue in 2022 to 33% in 2023, and the launch of Venus Prime, indicates a strategic move to improve cash flow, which is a common strategy for companies facing financial challenges.
• The company's focus on expanding into non-traditional markets is a strategy used by other medical device companies to increase market penetration and revenue growth.
• The company's reliance on third-party distributors is a common practice in the medical device industry, but it also introduces risks related to control and performance.
• The company's investment in research and development is consistent with industry trends, as innovation is crucial for maintaining a competitive edge.
• The company's exposure to global supply chain disruptions and currency fluctuations is a common risk for companies with international operations.

Related Party Transactions

• The company has distribution agreements with Technicalbiomed Co., Ltd. and Aexel Biomed Pte Ltd., where former senior officers of the company are shareholders.
• The company has entered into a Note Purchase and Registration Rights Agreement with EW Healthcare Partners, L.P. and EW Healthcare Partners-A, L.P., where a member of the Companys Board is affiliated.
• The company has sold securities in the 2023 Multi-Tranche Private Placement to EW Healthcare Partners, L.P. and related investment entities, where a member of the Companys Board is affiliated.
• The company has sold securities in the 2022 Private Placement to HealthQuest Partners II, L.P., where a member of the Companys Board is affiliated, EW Healthcare Partners, L.P. and related investment entities, where a member of the Companys Board is affiliated, Masters Capital Management, LLC and related investment entities, Masters Special Situations, LLC and related investment entities, Rajiv De Silva, Hemanth Varghese and Stanley Tyler Hollmig, M.D.

Stakeholder Impact

• Shareholders may experience dilution if the company sells shares of its common stock in future financings.
• Shareholders may not receive dividends on their common stock in the foreseeable future.
• Employees may be affected by the company's restructuring programs and workforce reductions.
• Customers may benefit from the company's new financing program, Venus Prime.
• Suppliers may be affected by the company's global supply chain disruptions and inflationary pressures.
• Creditors may be affected by the company's loan and security agreements and its ability to repay its debts.

Next Steps

• The company will continue to evaluate strategic alternatives to maximize shareholder value.
• The company will continue to focus on improving cash generation and reducing exposure to defaults and increased bad debt expense.
• The company will continue to invest in research and development to support its technology, marketing and post-marketing surveillance.
• The company will continue to focus on providing a complete set of products and services to the hair restoration market.
• The company will continue to focus on expanding into non-traditional markets.

Key Dates

Keywords

medical aesthetics, hair restoration, minimally invasive, non-invasive, robotic technology, energy-based devices, subscription model, Venus Prime, ARTAS, NeoGraft, AI.ME, financial results, corporate governance, intellectual property, regulatory compliance